Under the terms of the merger agreement, Sanofi will acquire DR-0201 through the acquisition of the Dren Bio affiliate ...

Below is Validea's guru fundamental report for SANOFI SA (ADR) (SNY). Of the 22 guru strategies we follow, SNY rates highest using our Acquirer's Multiple Investor model based on the published ...

It was developed with Sanofi (NASDAQ: SNY), who actually claims the revenues and splits profits with Regeneron. Regeneron posts their portion of Dupixent as collaboration revenue. Regeneron and ...

HighTower Advisors LLC increased its position in shares of Sanofi (NASDAQ:SNY – Free Report) by 3.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The ...

Jones Financial Companies Lllp raised its stake in Sanofi (NASDAQ:SNY – Free Report) by 55.0% during the 4th quarter, ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi presented positive results ... author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...

Sanofi develops therapeutic products for diabetes ... Here are a few to get you started, listed in alphabetical order. CoCrystal Pharma (NASDAQ:COCP) CoCrystal Pharma is a clinical-stage biotech ...

Sanofi (NASDAQ:SNY) has struck a major deal to acquire Dren Bios autoimmune disease treatment, DR-0201, reinforcing its ...

FDA’s Priority Tag to SNY’s Dupixent sBLA for Bullous Pemphigoid Sanofi and Regeneron announced that the FDA has accepted and granted priority review to an sBLA seeking approval of Dupixent ...

Saint Gobain, Sanofi and L'Oreal are up 1 to 1.2% ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...

First on this list of the top NASDAQ stem cell company stocks is multinational ... French multinational pharmaceutical company Sanofi develops therapeutic products for diabetes and cardiovascular ...